Background	B-O
Two	B-O
weeks’	B-O
isolation	B-O
is	B-O
widely	B-O
recommended	B-O
for	B-O
people	B-O
commencing	B-O
treatment	B-O
for	B-O
pulmonary	B-LF
tuberculosis	I-LF
(TB).	B-O
The	B-O
evidence	B-O
that	B-O
this	B-O
corresponds	B-O
to	I-LF
clearance	B-O
of	B-O
potentially	B-O
infectious	B-O
tuberculous	B-O
mycobacteria	B-O
in	B-O
sputum	B-O
is	B-O
not	B-O
well	B-O
established.	B-O
This	B-O
World	B-LF
Health	I-LF
Organization–commissioned	B-O
review	B-O
investigated	B-O
sputum	B-O
sterilisation	B-O
dynamics	B-O
during	B-O
TB	B-AC
treatment.	B-O
Methods	B-O
and	I-LF
findings	B-O
For	B-O
the	B-O
main	B-O
analysis,	B-O
2	B-O
systematic	B-O
literature	B-O
searches	B-O
of	B-O
OvidSP	B-O
MEDLINE,	B-O
Embase,	B-O
and	I-LF
Global	B-O
Health,	B-O
and	I-LF
EBSCO	B-O
CINAHL	B-O
Plus	B-O
were	B-O
conducted	B-O
to	I-LF
identify	B-O
studies	B-O
with	B-O
data	B-O
on	B-O
TB	B-AC
infectiousness	B-O
(all	B-O
studies	B-O
to	I-LF
search	B-O
date,	B-O
1	B-O
December	B-O
2017)	B-O
and	I-LF
all	B-O
randomised	B-LF
controlled	I-LF
trials	B-O
(RCTs)	B-O
for	B-O
drug-susceptible	B-O
TB	B-AC
(from	B-O
1	B-O
January	B-O
1990	B-O
to	I-LF
search	B-O
date,	B-O
20	B-O
February	B-O
2018).	B-O
Included	B-O
articles	B-O
reported	B-O
on	B-O
patients	B-O
receiving	B-O
effective	B-O
treatment	B-O
for	B-O
culture-confirmed	B-O
drug-susceptible	B-O
pulmonary	B-LF
TB.	B-O
The	B-O
outcome	B-O
of	B-O
interest	B-O
was	B-O
sputum	B-O
bacteriological	B-O
conversion:	B-O
the	B-O
proportion	B-LF
of	B-O
patients	B-O
having	B-O
converted	I-LF
by	B-O
a	B-O
defined	B-O
time	B-LF
point	B-O
or	B-O
a	B-O
summary	B-O
measure	B-O
of	B-O
time	B-LF
to	I-LF
conversion,	B-O
assessed	B-O
by	B-O
smear	B-O
or	B-O
culture.	B-O
Any	B-O
study	B-O
design	B-O
with	B-O
10	B-O
or	B-O
more	B-O
particpants	B-O
was	B-O
considered.	B-O
Record	B-O
sifting	B-O
and	I-LF
data	B-O
extraction	B-O
were	B-O
performed	B-O
in	B-O
duplicate.	B-O
Random	B-O
effects	B-O
meta-analyses	B-O
were	B-O
performed.	B-O
A	B-O
narrative	B-O
summary	B-O
additionally	B-O
describes	B-O
the	B-O
results	B-O
of	B-O
a	B-O
systematic	B-O
search	B-O
for	B-O
data	B-O
evaluating	B-O
infectiousness	B-O
from	B-O
humans	B-O
to	I-LF
experimental	B-O
animals	B-O
(PubMed,	B-O
all	B-O
studies	B-O
to	I-LF
27	B-O
March	B-O
2018).	B-O
Other	B-O
evidence	B-O
on	B-O
duration	B-O
of	B-O
infectiousness—including	B-O
studies	B-O
reporting	B-O
on	B-O
cough	B-O
dynamics,	B-O
human	B-O
tuberculin	B-LF
skin	I-LF
test	I-LF
conversion,	B-O
or	B-O
early	B-O
bactericidal	B-O
activity	B-O
of	B-O
TB	B-AC
treatments—was	B-O
outside	B-O
the	B-O
scope	B-O
of	B-O
this	B-O
review.	B-O
The	B-O
literature	B-O
search	B-O
was	B-O
repeated	B-O
on	B-O
22	B-O
November	B-O
2020,	B-O
at	B-O
the	B-O
request	B-O
of	B-O
the	B-O
editors,	B-O
to	I-LF
identify	B-O
studies	B-O
published	B-O
after	B-O
the	B-O
previous	B-O
censor	B-O
date.	B-O
Four	B-O
small	B-O
studies	B-O
reporting	B-O
3	B-O
different	B-O
outcome	B-O
measures	B-O
were	B-O
identified,	B-O
which	B-O
included	B-O
no	B-O
data	B-O
that	B-O
would	B-O
alter	B-O
the	B-O
findings	B-O
of	B-O
the	B-O
review;	B-O
they	B-O
are	B-O
not	B-O
included	B-O
in	B-O
the	B-O
meta-analyses.	B-O
Of	B-O
5,290	B-O
identified	B-O
records,	B-O
44	B-O
were	B-O
included.	B-O
Twenty-seven	B-O
(61%)	B-O
were	B-O
RCTs	B-O
and	I-LF
17	B-O
(39%)	B-O
were	B-O
cohort	B-O
studies.	B-O
Thirteen	B-O
studies	B-O
(30%)	B-O
reported	B-O
data	B-O
from	B-O
Africa,	B-O
12	B-O
(27%)	B-O
from	B-O
Asia,	B-O
6	B-O
(14%)	B-O
from	B-O
South	B-O
America,	B-O
5	B-O
(11%)	B-O
from	B-O
North	B-O
America,	B-O
and	I-LF
4	B-O
(9%)	B-O
from	B-O
Europe.	B-O
Four	B-O
studies	B-O
reported	B-O
data	B-O
from	B-O
multiple	B-O
continents.	B-O
Summary	B-O
estimates	B-O
suggested	B-O
smear	B-O
conversion	I-LF
in	B-O
9%	B-O
of	B-O
patients	B-O
at	B-O
2	B-O
weeks	B-O
(95%	B-O
CI	B-AC
3%–24%,	B-O
1	B-O
single	B-O
study	B-O
[	B-O
N	B-O
=	B-O
1]),	B-O
and	I-LF
82%	B-O
of	B-O
patients	B-O
at	B-O
2	B-O
months	B-O
of	B-O
treatment	B-O
(95%	B-O
CI	B-AC
78%–86%,	B-O
N	B-O
=	B-O
10).	B-O
Among	B-O
baseline	B-O
smear-positive	B-O
patients,	B-O
solid	B-O
culture	B-O
conversion	I-LF
occurred	B-O
by	B-O
2	B-O
weeks	B-O
in	B-O
5%	B-O
(95%	B-O
CI	B-AC
0%–14%,	B-O
N	B-O
=	B-O
2),	B-O
increasing	B-O
to	I-LF
88%	B-O
at	B-O
2	B-O
months	B-O
(95%	B-O
CI	B-AC
84%–92%,	B-O
N	B-O
=	B-O
20).	B-O
At	B-O
equivalent	B-O
time	B-LF
points,	B-O
liquid	B-O
culture	B-O
conversion	I-LF
was	B-O
achieved	B-O
in	B-O
3%	B-O
(95%	B-O
CI	B-AC
1%–16%,	B-O
N	B-O
=	B-O
1)	B-O
and	I-LF
59%	B-O
(95%	B-O
CI	B-AC
47%–70%,	B-O
N	B-O
=	B-O
8).	B-O
Significant	B-O
heterogeneity	B-O
was	B-O
observed.	B-O
Further	B-O
interrogation	B-O
of	B-O
the	B-O
data	B-O
to	I-LF
explain	B-O
this	B-O
heterogeneity	B-O
was	B-O
limited	B-O
by	B-O
the	B-O
lack	B-O
of	B-O
disaggregation	B-O
of	B-O
results,	B-O
including	B-O
by	B-O
factors	B-O
such	B-O
as	B-O
HIV	B-O
status,	B-O
baseline	B-O
smear	B-O
status,	B-O
and	I-LF
the	B-O
presence	B-O
or	B-O
absence	B-O
of	B-O
lung	B-O
cavitation.	B-O
Conclusions	B-O
This	B-O
systematic	B-O
review	B-O
found	B-O
that	B-O
most	B-O
patients	B-O
remained	B-O
culture	B-O
positive	B-O
at	B-O
2	B-O
weeks	B-O
of	B-O
TB	B-AC
treatment,	B-O
challenging	B-O
the	B-O
view	B-O
that	B-O
individuals	B-O
are	B-O
not	B-O
infectious	B-O
after	B-O
this	B-O
interval.	B-O
Culture	B-O
positivity	B-O
is,	B-O
however,	B-O
only	B-O
1	B-O
component	B-O
of	B-O
infectiousness,	B-O
with	B-O
reduced	B-O
cough	B-O
frequency	B-O
and	I-LF
aerosol	B-O
generation	B-O
after	B-O
TB	B-AC
treatment	B-O
initiation	B-O
likely	B-O
to	I-LF
also	B-O
be	B-O
important.	B-O
Studies	B-O
that	B-O
integrate	B-O
our	B-O
findings	B-O
with	B-O
data	B-O
on	B-O
cough	B-O
dynamics	B-O
could	B-O
provide	B-O
a	B-O
more	B-O
complete	B-O
perspective	B-O
on	B-O
potential	B-O
transmission	B-O
of	B-O
Mycobacterium	B-LF
tuberculosis	I-LF
by	B-O
individuals	B-O
on	B-O
treatment.	B-O
Trial	B-O
registration	B-O
Systematic	B-O
review	B-O
registration:	B-O
PROSPERO	B-O
85226	B-O
.	B-O
Author	B-O
summary	B-O
Why	B-O
was	B-O
this	B-O
study	B-O
done?	B-O
Though	B-O
cited	B-O
in	B-O
many	B-O
countries’	B-O
national	B-O
guidance,	B-O
the	B-O
evidence	B-O
that	B-O
individuals	B-O
with	B-O
pulmonary	B-LF
tuberculosis	I-LF
(TB)	B-O
are	B-O
rendered	B-O
non-infectious	B-O
by	B-O
2	B-O
weeks	B-O
of	B-O
effective	B-O
TB	B-AC
treatment	B-O
is	B-O
challenged.	B-O
This	B-O
systematic	B-O
review	B-O
was	B-O
commissioned	B-O
by	B-O
the	B-O
World	B-LF
Health	I-LF
Organization	I-LF
to	I-LF
provide	B-O
evidence	B-O
to	I-LF
inform	B-O
TB	B-AC
infection	B-LF
prevention	I-LF
and	I-LF
control	I-LF
guidelines.	B-O
We	B-O
sought	B-O
to	I-LF
synthesise	B-O
the	B-O
available	B-O
data	B-O
on	B-O
the	B-O
clearance	B-O
of	B-O
potentially	B-O
infectious	B-O
TB	B-AC
bacteria	B-O
from	B-O
the	B-O
sputum	B-O
of	B-O
patients	B-O
after	B-O
starting	B-O
effective	B-O
treatment.	B-O
What	B-O
did	B-O
the	B-O
researchers	B-O
do	B-O
and	I-LF
find?	B-O
We	B-O
performed	B-O
systematic	B-O
searches	B-O
of	B-O
literature	B-O
databases	B-O
to	I-LF
identify	B-O
relevant	B-O
articles,	B-O
using	B-O
predetermined	B-O
inclusion	B-O
criteria.	B-O
Extracted	B-O
data	B-O
were	B-O
synthesised	B-O
using	B-O
narrative	B-O
summaries	B-O
and	I-LF
meta-analyses.	B-O
A	B-O
minority	B-O
of	B-O
patients	B-O
had	B-O
clearance	B-O
of	B-O
TB	B-AC
bacteria	B-O
from	B-O
sputum	B-O
at	B-O
2	B-O
weeks	B-O
of	B-O
effective	B-O
treatment,	B-O
as	B-O
assessed	B-O
by	B-O
either	B-O
sputum	B-O
smear	B-O
or	B-O
culture.	B-O
As	B-O
expected,	B-O
the	B-O
proportion	B-LF
having	B-O
cleared	B-O
TB	B-AC
bacteria	B-O
from	B-O
sputum	B-O
increased	B-O
over	B-O
time;	B-O
however,	B-O
at	B-O
2	B-O
months	B-O
of	B-O
treatment	B-O
12%	B-O
and	I-LF
41%	B-O
of	B-O
patients	B-O
still	B-O
had	B-O
viable	B-O
TB	B-AC
bacteria	B-O
present,	B-O
as	B-O
assessed	B-O
by	B-O
solid	B-O
and	I-LF
liquid	B-O
culture,	B-O
respectively.	B-O
What	B-O
do	B-O
these	B-O
findings	B-O
mean?	B-O
The	B-O
presence	B-O
of	B-O
viable	B-O
TB	B-AC
bacteria	B-O
in	B-O
the	B-O
sputum	B-O
of	B-O
pulmonary	B-LF
TB	B-AC
patients	B-O
beyond	B-O
2	B-O
weeks	B-O
of	B-O
effective	B-O
treatment	B-O
suggests	B-O
individuals	B-O
may	B-O
be	B-O
infectious	B-O
for	B-O
longer	B-O
than	B-O
this	B-O
interval.	B-O
TB	B-AC
transmission	B-O
requires	B-O
the	B-O
presence	B-O
of	B-O
viable	B-O
mycobacteria	B-O
in	B-O
sputum	B-O
and	I-LF
a	B-O
mechanism	B-O
for	B-O
aerosol	B-O
or	B-O
droplet	B-O
spread.	B-O
Understanding	B-O
how	B-O
other	B-O
factors,	B-O
such	B-O
as	B-O
the	B-O
presence	B-O
of	B-O
cough,	B-O
change	B-O
during	B-O
treatment	B-O
is	B-O
also	B-O
important	B-O
for	B-O
TB	B-AC
infection	B-LF
prevention	I-LF
and	I-LF
control.	B-O
Tuberculosis	B-O
(TB)	B-O
is	B-O
the	B-O
leading	B-O
cause	B-O
of	B-O
death	B-O
from	B-O
an	B-O
infectious	B-O
disease	B-O
.	B-O
Mycobacterium	B-LF
tuberculosis	I-LF
(Mtb)	B-O
,	B-O
the	B-O
causative	B-O
organism,	B-O
is	B-O
transmitted	B-O
via	B-O
respiratory	B-O
droplet	B-O
nuclei	B-O
generated	B-O
by	B-O
individuals	B-O
with	B-O
pulmonary	B-LF
TB	B-AC
(PTB).	B-O
Transmission	B-O
is	B-O
affected	B-O
by	B-O
environmental	B-O
factors,	B-O
characteristics	B-O
of	B-O
both	B-O
the	B-O
source	B-O
case	B-O
and	I-LF
exposed	B-O
individual,	B-O
and	I-LF
the	B-O
nature	B-O
of	B-O
their	B-O
contact.	B-O
The	B-O
greatest	B-O
risk	B-O
is	B-O
from	B-O
individuals	B-O
with	B-O
smear-positive	B-O
PTB	B-AC
and	I-LF
high	B-O
cough	B-O
frequency	B-O
[	B-O
2	B-O
–	B-O
4	B-O
].	B-O
Interruption	B-O
of	B-O
transmission	B-O
requires	B-O
identification	B-O
and	I-LF
separation	B-O
of	B-O
infectious	B-O
individuals	B-O
until	B-O
they	B-O
are	B-O
rendered	B-O
non-infectious	B-O
through	B-O
treatment.	B-O
Multiple	B-O
countries’	B-O
national	B-O
guidance	B-O
documents	B-O
recommend	B-O
isolation	B-O
of	B-O
hospitalised	B-O
individuals,	B-O
with	B-O
2	B-O
weeks	B-O
of	B-O
effective	B-O
treatment	B-O
commonly	B-O
cited	B-O
as	B-O
the	B-O
time	B-LF
frame	B-O
after	B-O
which	B-O
patients	B-O
are	B-O
considered	B-O
non-infectious	B-O
[	B-O
5	B-O
–	B-O
9	B-O
].	B-O
Implementing	B-O
respiratory	B-O
isolation	B-O
has	B-O
considerable	B-O
resource	B-O
implications,	B-O
and	I-LF
is	B-O
often	B-O
unachievable	B-O
in	B-O
overstretched	B-O
health	B-O
systems	B-O
in	B-O
low-	B-LF
and	I-LF
middle-income	I-LF
countries,	B-O
where	B-O
the	B-O
greatest	B-O
burden	B-O
of	B-O
TB	B-AC
lies	B-O
.	B-O
The	B-O
evidence	B-O
base	B-O
for	B-O
the	B-O
2-week	B-O
‘rule’	B-O
has	B-O
been	B-O
repeatedly	B-O
challenged	B-O
by	B-O
data	B-O
demonstrating	B-O
that	B-O
most	B-O
baseline	B-O
sputum-culture-positive	B-O
patients	B-O
positive	B-O
remain	B-O
so	B-O
for	B-O
longer	B-O
than	B-O
14	B-O
days	B-O
.	B-O
These	B-O
individuals	B-O
are	B-O
potentially	B-O
infectious,	B-O
although	B-O
diminished	B-O
cough	B-O
frequency	B-O
may	B-O
reduce	B-O
transmission	B-O
[	B-O
4	B-O
,	B-O
11	B-O
].	B-O
This	B-O
systematic	B-O
review	B-O
was	B-O
commissioned	B-O
by	B-O
the	B-O
World	B-LF
Health	I-LF
Organization	I-LF
(WHO)	B-O
Department	B-O
of	B-O
Global	B-O
TB	B-AC
Programme	B-O
Guideline	B-LF
Development	I-LF
Group	I-LF
(GDG)	B-O
to	I-LF
synthesise	B-O
evidence	B-O
on	B-O
the	B-O
dynamics	B-O
of	B-O
potential	B-O
infectiousness	B-O
of	B-O
individuals	B-O
with	B-O
PTB	B-AC
receiving	B-O
effective	B-O
therapy,	B-O
informing	B-O
the	B-O
2019	B-O
guideline	B-O
update	B-O
on	B-O
TB	B-AC
infection	B-LF
prevention	I-LF
and	I-LF
control	I-LF
(IPC)	B-O
.	B-O
Potential	B-O
infectiousness	B-O
was	B-O
defined	B-O
here	B-O
as	B-O
detection	B-O
of	B-O
Mtb	B-AC
by	B-O
sputum	B-O
smear	B-O
or	B-O
culture,	B-O
irrespective	B-O
of	B-O
cough	B-O
dynamics	B-O
or	B-O
contact	B-O
mixing	B-O
patterns.	B-O
Whilst	B-O
smear	B-O
microscopy	B-O
may	B-O
detect	B-O
non-viable,	B-O
and	I-LF
therefore	B-O
non-infectious,	B-O
bacilli,	B-O
it	B-O
is	B-O
referenced	B-O
as	B-O
a	B-O
measure	B-O
of	B-O
treatment	B-O
response	B-O
in	B-O
published	B-O
guidelines	B-O
and	I-LF
in	B-O
clinical	B-O
practice.	B-O
Molecular	B-O
methods	B-O
(	B-O
Mtb	B-AC
DNA	B-O
detection,	B-O
e.g.,	B-O
Xpert	B-O
MTB/RIF	B-O
[Cepheid])	B-O
also	B-O
detect	B-O
non-viable	B-O
bacilli	B-O
and	I-LF
are	B-O
not	B-O
routinely	B-O
used	B-O
in	B-O
assessment	B-O
of	B-O
treatment	B-O
response;	B-O
such	B-O
assessments	B-O
were	B-O
excluded	B-O
from	B-O
this	B-O
analysis.	B-O
Two	B-O
types	B-O
of	B-O
evidence	B-O
were	B-O
considered:	B-O
(1)	B-O
data	B-O
on	B-O
time	B-LF
from	B-O
treatment	B-O
initiation	B-O
to	I-LF
sputum	B-O
smear	B-O
and	I-LF
culture	B-O
conversion	I-LF
and	I-LF
(2)	B-O
data	B-O
from	B-O
measurements	B-O
of	B-O
infectiousness	B-O
from	B-O
PTB	B-AC
patients	B-O
to	I-LF
experimental	B-O
animals.	B-O
Although	B-O
cough	B-O
is	B-O
clearly	B-O
important,	B-O
review	B-O
of	B-O
cough	B-O
dynamics	B-O
during	B-O
TB	B-AC
treatment	B-O
did	B-O
not	B-O
form	B-O
part	B-O
of	B-O
this	B-O
study.	B-O
Studies	B-O
evaluating	B-O
early	B-O
bactericidal	B-O
activity	B-O
and	I-LF
human-to-human	B-O
transmission	B-O
were	B-O
also	B-O
considered	B-O
outside	B-O
the	B-O
scope	B-O
of	B-O
this	B-O
study.	B-O
Methods	B-O
This	B-O
review	B-O
is	B-O
reported	B-O
following	B-O
Preferred	B-O
Reporting	B-O
Items	B-O
for	B-O
Systematic	B-O
Reviews	B-O
and	I-LF
Meta-Analyses	B-O
(PRISMA)	B-O
guidelines	B-O
.	B-O
Our	B-O
PRISMA	B-O
checklist	B-O
is	B-O
located	B-O
in	B-O
S1	B-O
PRISMA	B-O
Checklist	B-O
.	B-O
A	B-O
prospectively	B-O
registered	B-O
review	B-O
protocol	B-O
is	B-O
available	B-O
in	B-O
PROSPERO	B-O
(	B-O
,	B-O
study	B-O
ID	B-O
85226	B-O
[background	B-O
question	B-O
3]).	B-O
Search	B-O
strategy	B-O
A	B-O
professional	B-O
librarian	B-O
developed	B-O
and	I-LF
executed	B-O
the	B-O
literature	B-O
search,	B-O
in	B-O
consultation	B-O
with	B-O
the	B-O
WHO	B-AC
GDG.	B-O
The	B-O
population	B-O
of	B-O
interest	B-O
was	B-O
patients	B-O
receiving	B-O
an	B-O
effective	B-O
treatment	B-O
regimen	B-O
for	B-O
drug-susceptible	B-O
PTB	B-AC
(DS-TB);	B-O
the	B-O
outcome	B-O
of	B-O
interest	B-O
was	B-O
bacteriological	B-O
conversion	I-LF
of	B-O
sputum.	B-O
Effective	B-O
treatment	B-O
required	B-O
at	B-O
least	B-O
rifampicin	B-O
(R)	B-O
and	I-LF
isoniazid	B-O
(H)	B-O
throughout,	B-O
pyrazinamide	B-O
(Z)	B-O
for	B-O
the	B-O
2-month	B-O
intensive	B-O
phase,	B-O
and	I-LF
administration	B-O
at	B-O
least	B-O
5	B-O
days	B-O
per	B-O
week.	B-O
Inclusion	B-O
of	B-O
ethambutol	B-O
(E)	B-O
and	I-LF
streptomycin	B-O
(S)	B-O
was	B-O
permitted	B-O
but	B-O
not	B-O
essential.	B-O
Regimens	B-O
including	B-O
drugs	B-O
not	B-O
conventionally	B-O
regarded	B-O
as	B-O
first-line,	B-O
such	B-O
as	B-O
quinolones,	B-O
were	B-O
excluded	B-O
.	B-O
The	B-O
outcome	B-O
was	B-O
defined	B-O
as	B-O
either	B-O
the	B-O
proportion	B-LF
of	B-O
participants	B-O
achieving	B-O
bacteriological	B-O
(smear	B-O
or	B-O
culture)	B-O
conversion	I-LF
from	B-O
positive	B-O
to	I-LF
negative	B-O
by	B-O
fixed	B-O
time	B-LF
points	B-O
during	B-O
treatment	B-O
(proportion	B-O
converted	I-LF
[PC])	B-O
or	B-O
time	B-LF
to	I-LF
conversion	I-LF
(TTC)	B-O
for	B-O
the	B-O
study	B-O
population.	B-O
As	B-O
a	B-O
descriptive	B-O
analysis,	B-O
no	B-O
intervention	B-O
or	B-O
comparator	B-O
group	B-O
was	B-O
defined.	B-O
Full	B-O
search	B-O
parameters	B-O
are	B-O
detailed	B-O
in	B-O
S1	B-O
Table	B-O
and	I-LF
S2	B-O
Table	B-O
.	B-O
The	B-O
search	B-O
was	B-O
constructed	B-O
in	B-O
OvidSP	B-O
MEDLINE,	B-O
adapted	B-O
and	I-LF
run	B-O
in	B-O
OvidSP	B-O
Embase;	B-O
OvidSP	B-O
Global	B-O
Health;	B-O
and	I-LF
EBSCO	B-O
CINAHL	B-O
Plus.	B-O
Searches	B-O
used	B-O
subject	B-O
headings	B-O
where	B-O
available,	B-O
and	I-LF
search	B-O
terms	B-O
in	B-O
the	B-O
title	B-O
and	I-LF
abstract.	B-O
Combinations	B-O
of	B-O
terms	B-O
were	B-O
used	B-O
to	I-LF
capture	B-O
the	B-O
concepts	B-O
of	B-O
infectiousness	B-O
and	I-LF
TB.	B-O
Language	B-O
was	B-O
limited	B-O
to	I-LF
English,	B-O
Japanese,	B-O
Chinese,	B-O
Russian,	B-O
French,	B-O
Spanish,	B-O
and	I-LF
Portuguese.	B-O
On	B-O
initial	B-O
screening	B-O
of	B-O
search	B-O
results,	B-O
the	B-O
authors	B-O
noted	B-O
the	B-O
absence	B-O
of	B-O
several	B-O
randomised	B-LF
controlled	I-LF
trials	B-O
(RCTs)	B-O
known	B-O
to	I-LF
include	B-O
culture	B-O
conversion	I-LF
data	B-O
in	B-O
standard	B-O
treatment	B-O
arms.	B-O
An	B-O
additional	B-O
search	B-O
was	B-O
therefore	B-O
constructed	B-O
identifying	B-O
all	B-O
RCTs	B-O
of	B-O
DS-TB	B-O
treatment	B-O
in	B-O
humans.	B-O
The	B-O
first	B-O
search	B-O
was	B-O
conducted	B-O
on	B-O
1	B-O
December	B-O
2017	B-O
without	B-O
date	B-O
restrictions;	B-O
the	B-O
second	B-O
(RCT	B-O
search)	B-O
was	B-O
conducted	B-O
on	B-O
20	B-O
February	B-O
2018,	B-O
with	B-O
date	B-O
limited	B-O
to	I-LF
1990	B-O
onwards,	B-O
to	I-LF
identify	B-O
RCTs	B-O
incorporating	B-O
standard	B-O
daily	B-O
rifampicin-based	B-O
regimens.	B-O
To	B-O
mitigate	B-O
the	B-O
risk	B-O
of	B-O
overlooking	B-O
important	B-O
data	B-O
reported	B-O
since	B-O
our	B-O
search	B-O
censor	B-O
date,	B-O
during	B-O
manuscript	B-O
review	B-O
we	B-O
conducted	B-O
a	B-O
further	B-O
literature	B-O
search	B-O
of	B-O
OvidSP	B-O
MEDLINE	B-O
and	I-LF
Embase	B-O
on	B-O
22	B-O
November	B-O
2020.	B-O
We	B-O
used	B-O
the	B-O
original	B-O
search	B-O
terms	B-O
(	B-O
S1	B-O
Table	B-O
and	I-LF
S2	B-O
Table	B-O
)	B-O
combined	B-O
with	B-O
terms	B-O
identified	B-O
as	B-O
being	B-O
common	B-O
either	B-O
as	B-O
keywords	B-O
or	B-O
in	B-O
the	B-O
titles/abstracts	B-O
of	B-O
studies	B-O
already	B-O
included	B-O
in	B-O
the	B-O
review.	B-O
Full	B-O
details,	B-O
including	B-O
additional	B-O
search	B-O
terms,	B-O
are	B-O
provided	B-O
in	B-O
S1	B-O
Appendix	B-O
.	B-O
Study	B-O
selection	B-O
and	I-LF
data	B-O
extraction	B-O
Two-stage	B-O
sifting	B-O
by	B-O
2	B-O
independent	B-O
reviewers	B-O
was	B-O
employed,	B-O
applying	B-O
predetermined	B-O
eligibility	B-O
criteria	B-O
at	B-O
title	B-O
and	I-LF
abstract	B-O
review	B-O
and,	B-O
where	B-O
necessary,	B-O
full-text	B-O
screening.	B-O
